Management of high blood cholesterol levels in Nova Scotian adults: Comparison with the NCEP II and European Clinical Practice Guidelines

American Journal of Managed Care

Volumn 6, Issue 9, 2000, Pages 1017-1028

  Kephart, G ^a   Sketris, I ^a   MacLean, D ^a   Kass, K ^a   Nagpal, S ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; COLESTYRAMINE; LIPID;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; EDUCATION PROGRAM; EUROPE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CROSS-SECTIONAL STUDIES; GUIDELINE ADHERENCE; HEALTH SURVEYS; HUMANS; HYPERCHOLESTEROLEMIA; MIDDLE AGED; NOVA SCOTIA; PRACTICE GUIDELINES; PREVALENCE;

EID: 0033819268     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Changes in risk factors and the decline in mortality from cardiovascular disease: The Framingham Heart Study
2. Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow up in Whitehall Study
3. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
4. Periodic Health Examination, 1993 update: 2, lowering the blood total cholesterol level to prevent coronary heart disease
5. Prevention of coronary heart disease in clinical practice: Recommendations of the task force of the European Society of Cardiology, European Athrosclerosis Society, and the European Society of Hypertension
6. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease
7. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
8. The Lipid Research Clinics Coronary Primary Prevention Trial results II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
9. The Lipid Research Clinics Coronary Primary Prevention Trial results I: Reduction in incidence of coronary heart disease
10. The West of Scotland Coronary Prevention Study: Economic benefit analysis of primary prevention with pravastatin
11. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS: Air Force/ Texas Coronary Atherosclerosis Prevention Study
12. Conference review: Scientific session of the American College of Cardiology 1996
13. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group
14. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
15. Cholesterol lowering with statin drugs, risk of stroke and total mortality: An overview of randomized trials
16. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the treatment of patients with hypercholesterolemia: A meta-analysis of clinical trials
17. Comparison of efficacy and cost among lipid-lowering agents in patients with primary hypercholesterolemia
18. The use of statins: A case of misleading priorities?
19. Cholesterol-lowering therapy: Is there really a controversy?
20. The cholesterol controversy
21. Should there be a moratorium on the use of cholesterol lowering drugs?
22. Cost and health implications of cholesterol lowering
23. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: A review of recent developments
24. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy
25. Management of hyperlipidaemia: Guidelines of the British Hyperlipidaemia Association
26. Guidelines for the detection of high-risk lipoprotein profiles and the treatment of dyslipoproteinemias
27. Rationale for and outline of the recommendations of the working group on hypercholesterolemia and other dyslipidemias: Interim report
28. Effects of diet and exercise in men and post-menopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol
29. Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypocholesterolemic and combined hyperlipidemic men
30. Should a low-fat, high-carbohydrate diet be recommended for everyone? The case for a low-fat, high-carbohydrate diet
31. Should a low-fat, high-carbohydrate diet be recommended for everyone? Beyond low-fat diets
32. Dyslipidemia treatment guidelines and management systems in Kaiser Permanente
33. Evaluating the efficacy of the National Cholesterol Education Program adult treatment guidelines: Cholesterol lowering intervention program
34. Failure of implementation of the National Heart Foundation of New Zealand guidelines for the management of dyslipidaemia
35. Prevention of coronary heart disease in clinical practice: A commentary on current treatment patterns in six European countries in relation to published recommendations
36. Cholesterol management in Dutch practice
37. Early detection and treatment of hyperlipidemia: Physician practices in Canada
38. Impact of different blood lipid evaluation and treatment guidelines on the proportion of Canadians identified and treated with elevated blood cholesterol
39. Analysis of large health surveys: Accounting for the sampling design
40. Indications for cholesterol-lowering medication: A comparison of risk-assessment methods
41. Treating hyperlipidemia for the primary prevention of coronary disease: Are higher dosages of lovastatin cost-effective?
42. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease
43. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: An updated Sheffield table
44. Discontinuation of antihyperlipidemic drugs: Do rates reported in clinical trials reflect rates in primary care settings?
45. Persistence of use of lipid-lowering medications: A cross-national study
46. Apparent discontinuation rates in patients prescribed lipid-lowering drugs